Roche receives approval for cancer drug Columvi in Switzerland
Published: Wednesday, Nov 15th 2023, 07:40
Retour au fil d'actualité
The pharmaceutical company Roche has received approval from Swissmedic. This concerns the drug Columvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
This lymphoma is one of the most aggressive, as Roche announced on Wednesday. Columvi (glofitamab) is the first bispecific "CD20xCD3 T cell-recruiting" antibody for the treatment of this lymphoma.
Swissmedic's approval is based on the results of a Phase I/II clinical trial. According to Roche, it showed a sustained response in patients with an overall response rate of over 55 percent. More than 40 percent of patients who had previously received CAR-T cell treatment also responded completely to treatment with Columvi.
Columvi is administered over a limited period of up to 8.5 months. This offers patients the possibility of a treatment-free period after the end of therapy, it is said.
Roche has already received approval for Columvi for the same indication in the USA and the European Union.
©Keystone/SDA
French 
English 
German 
Spanish 
Arabic